Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos NV    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 101.05 EUR in weekly data.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 157.6 EUR
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
GALAPAGOS NV-43.65%8 113
LONZA GROUP AG61.38%46 348
MODERNA, INC.416.51%39 979
CELLTRION, INC.66.30%36 064
IQVIA HOLDINGS INC.10.39%32 701
SEAGEN INC.47.09%30 304
IMMUNOMEDICS, INC.315.22%20 324
-
INCYTE CORPORATION-6.17%17 824
HANGZHOU TIGERMED CONSULTIN..85.76%15 612
ALNYLAM PHARMACEUTICALS, IN..6.82%14 293
PPD, INC.0.00%11 846
PHARMARON BEIJING CO., LTD.92.08%11 758
BIO-TECHNE CORPORATION38.37%11 727
CHARLES RIVER LABORATORIES ..52.23%11 541
QIAGEN N.V.38.55%10 703
ICON PUBLIC LIMITED COMPANY9.87%9 912
More Results
Financials
Sales 2020 526 M 625 M 625 M
Net income 2020 -328 M -390 M -390 M
Net cash 2020 3 599 M 4 275 M 4 275 M
P/E ratio 2020 -22,8x
Yield 2020 -
Capitalization 6 848 M 8 137 M 8 134 M
EV / Sales 2020 6,18x
EV / Sales 2021 6,36x
Nbr of Employees 1 407
Free-Float 74,4%
Upcoming event on GALAPAGOS NV
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes